Market Overview
In today's tumultuous trading session, the markets navigated a complex web of geopolitical tensions, sector-specific dynamics, and corporate developments, leaving investors to ponder the implications for tomorrow. The day's narrative was dominated by the escalating US-Iran tensions, which, despite their potential for disruption, were somewhat overshadowed by the resilience of the broader market. The Dow Jones Industrial Average surged over 1,000 points, while the Nasdaq rallied nearly 3%, underscoring a robust appetite for risk among investors, even as oil prices dipped to their lowest since August amid diplomatic efforts to mediate the conflict. Central to today's market movements was Nvidia, whose shares tumbled 4.3% following revelations of a probe into CEO Jensen Huang's alleged involvement with an executive suspected of Chinese espionage. This development not only raised questions about Huang's future but also cast a spotlight on the broader implications for the semiconductor industry, particularly concerning chip sales to China. Despite these concerns, Nvidia's troubles did not dampen the market's overall momentum, suggesting that investors may view potential restrictions on Nvidia's international operations as an opportunity for competitors within the AI ecosystem. The interplay between macroeconomic factors and corporate narratives was further exemplified by the broader geopolitical landscape. President Trump's closed-door discussions with Qatar's Prime Minister and his comments on the improbability of new strikes on Iran highlighted the delicate balance of diplomacy and military strategy, influencing market sentiment and commodity prices. On the corporate front, Nvidia's situation was compounded by revelations of its general counsel's intervention in a US government probe, raising questions about the company's influence over investigations into China chip curbs. This episode not only underscores the intricate relationship between corporate actions and geopolitical tensions but also highlights the potential for regulatory scrutiny in an increasingly complex global landscape. As investors look ahead, the market's resilience in the face of geopolitical volatility and corporate scandals suggests a cautious optimism. However, the unfolding developments around Nvidia, coupled with the broader geopolitical tensions and inflationary pressures, underscore the need for vigilance. The interplay between these macro and micro-level factors will undoubtedly continue to shape market dynamics, requiring investors to navigate a landscape marked by uncertainty and opportunity. In summary, today's market movements reflect a complex tapestry of geopolitical tensions, sector-specific dynamics, and corporate developments. As the market closes, investors are left to ponder the implications of these factors for the future, with a keen eye on the evolving geopolitical landscape and its impact on corporate fortunes. The coming days will be crucial in determining whether today's resilience is a harbinger of sustained market strength or a temporary reprieve in an increasingly uncertain global environment.
In today's after-hours trading, the US stock market demonstrated resilience amid a backdrop of geopolitical tensions and corporate developments, with sector ETFs reflecting varied responses to these dynamics. The Dow Jones and Nasdaq's strong performance, despite escalating US-Iran tensions, suggests a robust appetite for risk, which was mirrored in the sector ETF movements. The standout performer was the Industrial Select Sector SPDR Fund (XLI), which surged by 3.8%, likely buoyed by the broader market's risk-on sentiment and potential defense-related spending amid geopolitical uncertainties. Similarly, the Technology Select Sector SPDR Fund (XLK) saw a 3.7% increase, possibly driven by investor optimism in tech resilience despite Nvidia's 4.3% drop due to espionage allegations. This divergence highlights the market's ability to compartmentalize corporate-specific issues, viewing them as isolated rather than systemic risks. The Consumer Discretionary Select Sector SPDR Fund (XLY) also performed well, rising by 2.9%, reflecting consumer confidence and spending power in a risk-friendly environment. Financials (XLF) and Health Care (XLV) sectors, with gains of 1.5% and 1.9% respectively, benefited from the overall market optimism and potential interest rate implications. Energy (XLE) and Materials (XLB) sectors, with modest gains of 0.5% and 1.9%, indicate a cautious approach, possibly due to fluctuating oil prices and ongoing supply chain considerations. Real Estate (XLRE) and Utilities (XLU) sectors, both gaining around 1.5%, suggest a flight to stability, offering a hedge against volatility. The Consumer Staples Select Sector SPDR Fund (XLP) saw the smallest gain at 0.9%, reflecting its typical defensive nature in uncertain times. Looking ahead, the market's ability to absorb geopolitical and corporate shocks will be tested. While today's momentum suggests continued optimism, the unfolding Nvidia saga and geopolitical developments could introduce volatility. Investors will need to remain vigilant, balancing the current risk appetite with potential regulatory and geopolitical headwinds. The coming sessions will be crucial in determining whether today's resilience is sustainable or merely a temporary reprieve in an increasingly complex global landscape.
Market Insights
U.S. equities edged higher in subdued trading, with the advance largely driven by tech megacaps, while broader market participation waned. More than two-thirds of advancing stocks did so on below-average volume, suggesting that institutional desks remained largely on the sidelines despite the green tape. This divergence in volume and performance hints at potential tape fragility under light volume conditions. Mega-caps, with an average return of 3.45% and a beta of 1.16, outperformed the broader market, indicating their resilience and potential stability in the current environment. High-beta stocks, with a beta greater than 1.5, delivered the highest average return of 5.30%, reflecting their higher risk and potential reward profile. This performance gradient among beta cohorts highlights the market's tilt towards riskier assets. While market breadth superficially favored bulls, the lack of volume confirmation leaves the market vulnerable to sharp reversals if macroeconomic headlines trigger sudden selling. The absence of institutional volume in most advancers underscores the fragility of the current market advance.
Next Day Option Data
QQQ
SPY
IWM
6-K/8-K Form Update
STI
Solidion Technology, Inc. reported its third quarter 2026 financial results, showcasing strong liquidity with a cash balance of $26.2 million and a 40% reduction in total liabilities to $7.5 million. The company achieved a positive net income of $244,000 and maintained a working capital of $19.6 million. Solidion highlighted technological advancements, including the PEAK Series UPS for AI data centers, and announced a share repurchase program of up to $1.0 million, alongside board expansion and a focus on opportunistic acquisitions in the battery storage sector.
VDTA
Vertical Data Inc. secured $4.24 million in a private placement of common stock at $3.00 per share, issuing 1,413,640 shares, with B. Riley Securities as placement agent and Goldman Sachs LLC as exclusive capital markets advisor. Chairman and CEO Deven Soni, along with other insiders, purchased $1 million worth of shares, representing about 24% of the total proceeds from insiders. The company is actively pursuing an uplisting to a national stock exchange to support continued growth and expansion.
CWCO
Consolidated Water Co. Ltd. reported a third-quarter 2026 revenue decrease of 11.9% to $30.9 million, primarily due to declines in services and manufacturing revenue. Retail revenue rose 5.7% to $8.2 million, and bulk revenue increased 20.8% to $10.1 million, driven by new desalination plants in the Cayman Islands and Bahamas. Net income from continuing operations fell to $2.4 million or $0.15 per diluted share, compared to $5.6 million or $0.34 per diluted share in the same period in 2025. The company also announced a new 25-year retail water license in Grand Cayman, effective August 1, 2026.
MAPS
WM Technology, Inc. reported a decline in third-quarter revenue and Adjusted EBITDA, primarily due to client payment challenges, increased marketing expenses, and one-time costs such as a securities litigation settlement and severance payments. Revenue fell to $38.5 million from $42.2 million, with average monthly paying clients dropping to 4,899 from 5,221, and average monthly revenues per client decreasing to $2,618 from $2,693. The company posted a net loss of $5.9 million, compared to a net income of $3.6 million in the prior year, with Adjusted EBITDA at $0.8 million, down from $7.6 million.
MVSTW
Microvast faces significant financial risks, including potential delisting from Nasdaq due to challenges in meeting debt obligations and maintaining liquidity. In Q3 2026, the company reported a net loss of $X million, with adjusted EBITDA of $Y million and adjusted net profit/loss of $Z million, reflecting declining revenue and increased operating expenses. Microvast's financial performance is heavily dependent on product demand, regulatory changes, and the successful commercialization of its KAF electric powertrain platform, while also being exposed to geopolitical and economic risks.
SMC
Summit Midstream Corporation reported its third quarter 2026 financial and operating results, highlighting a net income of $15.9 million and Adjusted EBITDA of $70.7 million, marking a 16% increase from the previous quarter. The company raised its 2026 Adjusted EBITDA guidance to $250 million to $260 million, driven by strong producer activity and increased Rockies volumes, with a year-end total net leverage ratio expected at approximately 3.6x. Notable achievements include a record 1,002 MMcf/d throughput on the Double E Mainline and a 32% increase in Rockies Segment Adjusted EBITDA to $40.0 million.
TDGMW
Tidewater, Inc. completed the acquisition of Wilson, Sons Ultratug Participações S.A. and Atlantic Offshore Services S.A. for an aggregate cash purchase price of $283.1 million, adjusted for debt and other factors. The acquisition significantly expands Tidewater's presence in Brazil's offshore market by adding 22 platform supply vessels to its fleet, strengthening its competitive position.
ELMT
The Elmet Group Co. secured a landmark $450 million investment from the Department of War to bolster its tungsten supply chain, leading to a nearly 298% increase in backlog to $347.4 million. In the third quarter of 2026, revenue surged 55.6% to approximately $79.6 million, with gross profit margin expanding 960 basis points to 31.3%, and adjusted EBITDA increasing 129.4% to approximately $17.0 million, or 21.3% of revenue. The company's strategic investments, including partnerships and manufacturing expansions, underscore its robust growth strategy in aerospace, defense, and government markets.
BALY
Bally's Corporation reported a 21.7% year-over-year increase in consolidated revenue to $807.6 million for the third quarter ended September 30, 2026. The growth was driven by strong performances across its segments, including a 3.2% rise in Casinos & Resorts revenue to $408.6 million, a 22.8% increase in Bally's Intralot B2C revenue to $257.5 million, and a 25.6% rise in North America Interactive revenue to $62.7 million. Bally's also closed financing for its Bronx project, securing $400 million with an additional $160 million available for future draws.
QXO-PB
QXO, Inc. announced a $1 billion cash investment in CKX Lands, a public company listed on the NYSE American. The investment, led by Chairman and CEO Brad Jacobs with $900 million and co-investors contributing $100 million, aims to transform CKX into a growth platform. Existing stockholders will receive an upfront cash payment of $20.8 million, retain current business value, and participate in future upside.
NANO
Forge Nano Holdings, Inc. agreed to acquire HzO, Inc. through a merger consummated on November 4, 2026, with HzO becoming a wholly-owned subsidiary. The transaction, structured as a tax-qualifying reorganization, involves converting HzO's equity into Forge Nano Common Stock, with a purchase price of $55 million plus adjustments. Post-merger, Forge Nano issued 5,772,645 shares, with additional shares contingent on certain conditions.
CATX
Perspective Therapeutics, Inc. reported financial results for the quarter ended September 30, 2026, with cash, cash equivalents, and short-term investments totaling approximately $202 million, sufficient to fund planned clinical milestones and operational investments through 2028. The company highlighted positive interim data from Phase 1/2a bamzireotide navoxetan (VMT-α-NET) for neuroendocrine tumors and completed enrollment in Cohort 4 of its dose-finding study. Additionally, lapemelanotide zapixetar (VMT01) showed durable disease control in MC1R-positive melanoma, and PSV359 received Fast Track Designation from the FDA for FAP-positive solitary fibrous tumors, with a collaboration with Merck to evaluate PSV359 in combination with Keytruda® for certain lung and colorectal cancers.
KBR
KBR announced the formation of Trinzic, a national security, space, and technology company, resulting from the planned spin-off of its Mission Technology Solutions business, expected to launch on January 4, 2027. The new company, to be chaired by retired U.S. Air Force lieutenant general Wendy M. Masiello, will enter the market with over $5 billion in annual revenue, 20,000 employees, and a global footprint, focusing on high-priority missions across national security, human performance, global operations, and space. The board appointments are subject to final approval by KBR's Board of Directors and customary conditions.
DSP
Viant Technology Inc. reported robust third-quarter 2026 financial results, with revenue surging 29% year-over-year to $110.4 million. Adjusted EBITDA rose 24% to $19.8 million, and the company expanded its stock repurchase program to a total of $150 million. Viant acquired Waymark, a generative AI video creative production platform, and launched the TVision mobile meter to enhance CTV advertising, projecting fourth-quarter revenue between $130.5 million and $133.5 million.
USPH
U.S. Physical Therapy, Inc. reported third-quarter 2026 results, with physical therapy visits growing 8% and total revenue increasing 13%, driven by strong performance in traditional and industrial injury prevention divisions. The company completed major hospital partnerships in New York and Gulf Coast regions, resulting in higher net rates per visit and over 13% hospital revenue. EBITDA grew over 16%, though self-insured group health costs remained elevated due to large complex claims, increasing employee insurance claims expense by $7 million year-to-date. The company is taking action to address these costs.
CNNE
Cannae Holdings, Inc. has been actively monetizing nonstrategic assets to focus on sports and entertainment investments, generating $793 million in proceeds since 2025. The company sold interests in Watkins and Brasada Ranch and closed remaining O'Charley's restaurants. Cannae has invested in sports and entertainment assets, including a $22 million investment in Black Knight Football and the acquisition of Exeter Rugby Group, while enhancing operating performance and transparency across its portfolio.
LINC
Lincoln Educational Services Corporation reported strong third-quarter 2026 financial results, with student starts increasing by 14.2% to 7,362 and revenue growing 12.6% to $159.2 million. Adjusted EBITDA surged nearly 31% to $17.4 million, while net income rose 24.1% to $4.7 million. Year-to-date, revenue climbed 18.7% to $445.7 million, and adjusted EBITDA jumped 49.0% to $45.6 million. The company also acquired a campus in Melrose Park, Illinois, signed new leases in Tempe, Arizona, and Suitland, Maryland, and repurchased 871,135 shares for $21.0 million, increasing its share repurchase authorization to $70 million.
AVIR
Atea Pharmaceuticals, Inc. reported positive topline results from its Phase 3 C-BEYOND trial, demonstrating statistical non-inferiority of its bemnifosbuvir/ruzasvir regimen compared to Epclusa in treating hepatitis C in North America. The company anticipates results from its Phase 3 C-FORWARD trial in early 2027, supporting a New Drug Application submission to the FDA by mid-2027. Additionally, Atea secured up to $200 million in non-dilutive funding from Hercules Capital and advanced its chronic hepatitis E virus program.
EVI
EVI Industries, Inc. reported record first fiscal quarter results for the quarter ended September 30, 2026, with revenue increasing 4.3% to $112.9 million and net income surging 108% to $3.8 million. The company's gross profit rose 12% to $38.0 million, while operating income jumped 75% to $6.2 million. Net debt increased to $76.7 million, reflecting ongoing investments to enhance growth capabilities.
OXY-WT
Occidental Petroleum Corporation achieved a $10.0 billion principal debt milestone in the third quarter of 2026, reducing its principal debt by $1.8 billion. The company generated $4.1 billion in operating cash flow from continuing operations and delivered $2.8 billion in free cash flow before working capital, with capital expenditures totaling $1.3 billion. Global production reached 1,427 Mboed, exceeding guidance, while midstream and marketing pre-tax adjusted income surpassed expectations, reporting EPS of $1.61 and adjusted EPS from continuing operations of $1.91.
SECZ
Securitize Corp. reported third-quarter 2026 financial results, showcasing a record average of $5.0 billion in Tokenized Assets on its platform, a 39% year-over-year increase, with total Tokenized Assets reaching $4.8 billion as of September 30, 2026, up 9%. The company's total revenue hit $18.6 million, marking a 13% growth from the prior year, while the net loss for the quarter was $66.3 million, primarily due to non-cash expenses and accounting charges. Securitize also announced the acquisition of River One, expected to close in Q4 2026, enhancing its tokenization infrastructure and expanding into asset-backed finance.
CWST
Casella Waste Systems, Inc. reported third-quarter 2026 revenues of $559.2 million, up 15.2% year-over-year, driven by acquisition growth, positive pricing, and landfill volume increases. The company's solid waste pricing rose 5.5%, with collection and disposal price growth of 5.9% and 4.8%, respectively. Despite a net loss of $(7.0) million due to an impairment charge, Adjusted EBITDA reached $133.5 million, up 11.4% year-over-year, and net cash from operations increased 3.7% to $241.8 million.
USAR
USA Rare Earth, Inc. secured compliance and achieved significant operational milestones in its third quarter and nine months ended September 30, 2026. The company completed Stage 1 of the Serra Verde optimization and expansion program, commenced commercial-scale Mixed Rare Earth Carbonate production, and sold the first NdFeB permanent magnets at its Stillwater facility. Additionally, USA Rare Earth broke ground on a new facility in Blacksburg, South Carolina, and completed the acquisition of Serra Verde, enhancing its integrated rare earth and permanent magnet platform.
LIFX
Life360, Inc. reported a 40% year-over-year revenue increase to $174.1 million for Q3'26, with adjusted EBITDA reaching $34.6 million, a 20% margin. The company expanded its global paying circles by 26% to 3.4 million and achieved 188,000 quarterly net adds, a 10% increase. Monthly active users grew by 17% to 107.7 million, with a 21% rise in international MAU, bolstered by new B2B partnerships for international expansion.
CWEN
Clearway Energy, Inc. reported third-quarter 2026 financial results, showcasing a net income of $123 million and adjusted EBITDA of $435 million. The company's operational performance improved, with a generation availability factor of 93.8% and a 12% increase in renewables and storage segment generation compared to the same period in 2025. Liquidity stood at $1,102 million as of September 30, 2026, bolstered by $600 million in senior unsecured notes issued, and the company reaffirmed its 2026 guidance while setting a 2031 CAFD target range of $3.20 to $3.40 per share, indicating a 7-8% compound annual growth rate from 2025.
ZSTK
ZeroStack Corp. has agreed to transfer all business interests and shares to New Horizon Pharma B.V. and Phatebo GmbH, with the transaction closing on November 3, 2026, subject to certain conditions. The deal's value is pegged to a fixed EUR to INR exchange rate of 1.00 EUR = 110.00 INR, contingent upon due diligence completion and regulatory approvals. The agreement includes provisions for confidential information disclosure, a data room for due diligence, and executive management appointments to ensure compliance with Nasdaq, German, and Texas corporate laws.
GHI
Greystone Housing Impact Investors LP (NYSE: GHI) reported third quarter 2026 financial results, showing a net income of $3.2 million or $0.09 per Beneficial Unit Certificate (BUC), and a Cash Available for Distribution (CAD) of $3.8 million or $0.17 per BUC. The Partnership announced a call on November 10, 2026, to discuss results and business outlook, continuing its strategy to shift capital from joint venture equity investments in market rate multifamily properties to tax-exempt mortgage revenue bond investments. As of September 30, 2026, borrowers of MRBs and GILs were current on debt service obligations, with exceptions for five MRBs linked to a single borrower, and the Partnership reported advances and acquisitions totaling approximately $39.2 million.
OSG
Octave Specialty Group, Inc. reported a 35% increase in total revenue for its Insurance Distribution segment to $58 million in Q3 2026, driven by 23% organic growth and the acquisition of ArmadaCare. The Specialty P&C Insurance segment, under the Everspan brand, saw a 44% rise in net premiums written to $26 million. The company's net loss to shareholders decreased to $(4.2) million from $(5.4) million in the prior year, with adjusted EBITDA to shareholders rising to $8.3 million from $6.0 million.
AAON
AAON, Inc. reported record third-quarter revenue of $707.4 million, marking an 84.1% year-over-year increase, and raised its full-year outlook. The company noted a restatement of its first and second quarter 2026 financials due to revenue calculation errors, increasing first-half net sales by $10.7 million and diluted EPS by $0.09. AAON identified a material weakness in internal controls and is working on remediation, projecting 2026 net sales growth of 72%-75% and gross margins around 26%.
ZNTL
Zentalis Pharmaceuticals, Inc. reported its financial results for the quarter ended September 30, 2026, and provided business updates. The company plans to present information on its development of azenosertib, a WEE1 inhibitor, at investor conferences, highlighting its potential for treating PROC patients with Cyclin E1-positive tumors. Forward-looking statements include projected cash runway, planned clinical trials, and regulatory strategy, with risks such as limited operating history and potential regulatory challenges.
LRMR
Larimar Therapeutics, Inc. has completed its rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for accelerated approval of nomlabofusp to treat Friedreich's ataxia (FA). The submission includes FDA alignment on using skin frataxin as a potential novel surrogate endpoint, supported by open label data showing increased skin frataxin and clinical improvements. Larimar is currently enrolling patients in its global confirmatory Phase 3 study, FORWARD-FA, to further evaluate the treatment's efficacy.
PUBM
PubMatic, Inc. reported record third-quarter 2026 financial results, with revenue of $79.6 million, up 17% year-over-year, and adjusted EBITDA of $26.0 million, or a 33% margin, compared to $11.2 million, or 16% margin, in the same period of 2025. The company expanded its share repurchase program, authorizing an increase to $150 million and extending the term through December 31, 2028, allowing for repurchase of up to approximately $198 million of Class A common stock. Investments in advertiser performance are driving faster, more profitable growth, with CTV, Mobile App, and Emerging Revenues representing approximately 64% of total revenue.
KMPB
Kemper Corporation reported a net income of $0.88 per diluted share for the third quarter of 2026, reversing a loss of $(7.90) per share in the same period last year. The company's Personal Auto segment improved underwriting profitability, with a loss ratio decreasing to 103.3% from 105.5%, and a combined ratio of 99.2%, down from 105.0%. The Commercial Auto segment also saw an underwriting combined ratio of 97.8%, up from 93.7%, while Life Insurance revenues remained stable at $153 million. Kemper is enhancing its distribution model to optimize customer acquisition and distribution economics.
CSQR
Csquare, Inc. reported third-quarter 2026 results, showcasing a 25.6% year-over-year revenue growth to $302.3 million, driven by sustained demand and customer deployments. The company achieved record bookings of $66.1 million, marking its 14th consecutive quarter of sequential growth, despite a net loss of $88.1 million due to higher interest expenses and IPO-related costs. Adjusted EBITDA increased 44.3% to $132.1 million, with a margin expansion to 47.8%, reflecting disciplined execution and a recurring business model. Csquare also completed its IPO, issuing 50 million shares at $21.00 each, and began trading on the NYSE under the ticker NYSE:CSQR.
NRDY
Nerdy Inc. reported third-quarter 2026 results, with non-GAAP Adjusted EBITDA improving by $4.5 million year-over-year and the margin expanding by over 1,000 basis points. The company launched a redesigned, messaging-first student experience and advanced new self-service e-commerce capabilities, marking a shift towards a modern transaction model. Despite fewer new learning membership customers than anticipated, Nerdy expects to lower acquisition costs and support a more efficient go-to-market model, with Q4 revenue reflecting this shortfall.
KLTR
Kaltura, Inc. reported third-quarter financial results ending September 30, 2026, with total revenue of $47.3 million, surpassing high-end guidance. The company achieved record quarterly total and subscription revenue, with subscription revenue at $45.9 million, and its highest third-quarter adjusted EBITDA, while new subscription bookings more than doubled. Kaltura's outlook for the fourth quarter and full year 2026 anticipates record high annual results, with adjusted EBITDA expected between $19.5 million and $20.5 million for the full year.
SANM
Sanmina Corporation reported unaudited financial results for its fiscal quarter ended October 3, 2026, with revenue of $3.86 billion and non-GAAP diluted EPS of $4.43. For fiscal year 2026, revenue reached $14.53 billion, with non-GAAP diluted EPS at $13.28. Additionally, the company secured a senior secured credit agreement with Bank of America, N.A., including a $70 million increase in term A loans and an extended maturity date to October 28, 2031.
AVBP
ArriVent BioPharma, Inc. reported its third quarter 2026 financial results, highlighting continued enrollment in its pivotal Phase 3 ALPACCA study for first-line EGFR PACC-mutant NSCLC, with firmonertinib 240 mg showing promising antitumor activity and safety. The company also presented encouraging Phase 1 data for CDH17-targeted ADC ARR-217 at ESMO 2026, with a 44.8% objective response rate at 6 mg/kg, and initiated dosing in a Phase 1a/1b study of dual-target MUC16/NaPi2b tetravalent ADC ARR-002 for advanced or metastatic ovarian or endometrial cancer. ArriVent announced the retirement of Stuart Lutzker, M.D., Ph.D., and the appointment of Priti Patel, M.D., M.S., as Chief Medical Officer, with cash and investments of $393.2 million expected to fund operations through mid-2028.
SBET
Sharplink, Inc. reported a robust financial performance for the quarter ending September 30, 2026, with revenue climbing 24% to $13.5 million, driven by a surge in staking revenue. Net income soared to $751.4 million, or $3.45 per diluted share, primarily due to significant unrealized and realized gains on crypto assets. The company's ETH holdings expanded to approximately 892,708 ETH, and it completed a $200 million Lido staking allocation, launched a $125 million Galaxy Sharplink Onchain Yield Fund, and made a strategic equity investment in Blockspace.
PAYS
Paysign, Inc. reported record third-quarter 2026 revenue of $30.8 million, up 42.6% from the prior quarter, driven by growth in patient affordability and pharma revenue. The company's gross profit margin increased to 64.7% from 56.3%, while operating margin rose to 23.8% from 7.3%, reflecting improved profitability. Paysign exited the quarter with $34.54 million of unrestricted cash and no bank debt, raising guidance for key financial metrics and reaffirming its full-year revenue outlook of $114.0 million to $117.0 million.
RLGT
Radiant Logistics, Inc. reported robust financial results for the quarter ending September 30, 2026, with revenues surging 23.4% to $279.8 million and net income soaring 369.2% to $6.1 million. The company's profitability and margins expanded significantly, supported by a strengthened $200 million credit facility with no net debt. Additionally, Radiant Logistics expanded its transportation and logistics capabilities by acquiring the Dallas operations of Whitacre Logistics Services, LLC.
IMNM
Immunome, Inc. announced its third quarter 2026 financial results, highlighting a PDUFA target action date for varegacestat set for April 28, 2027, and EMA validation for its MAA targeting desmoid tumors. The company initiated a Phase 1 trial of IM-1021, with data expected at the 2026 American Society of Hematology Annual Meeting, and received IND clearance for IM-1340, with Phase 1 trials anticipated by year-end. Immunome's cash, cash equivalents, and marketable securities totaled $461.6 million as of September 30, 2026, projected to support operations through 2028.
PSKY
Skydance Media reported Paramount Skydance Q3 2026 net earnings of $73 million and adjusted EBITDA of $1.0 billion, with a 14% margin on $7.0 billion in revenue, up 5% year-over-year. Paramount+ revenue grew 21%, studios revenue surged 23%, and TV Media achieved a 34% adjusted EBITDA margin. The combined company aims to achieve $6 billion in annualized synergies within three years, reduce net leverage to 3.0x by 2029, and reach investment-grade credit metrics.
AMCX
AMC Global Media Inc. reported third-quarter 2026 results, with consolidated revenue growth driven by licensing and streaming businesses, despite an operating loss of $42 million and adjusted operating income of $70 million, down from $94 million and $185 million, respectively, in the prior year. Domestic operations revenue increased 2% to $495 million, while international revenue decreased 5% to $73 million. The company announced new content deals, including The Walking Dead Universe Collection on AMC+, a co-production with Netflix, and partnerships with Alcon Entertainment and StudioCanal, while divesting its ALLBLK streaming business for a $3.7 million pre-tax gain and entering an accelerated share repurchase agreement for $30 million of Class A Common Stock.
HPK
HighPeak Energy, Inc. (NASDAQ: HPK) reported third quarter 2026 financial results, revealing a net loss of $55.7 million or ($0.44) per diluted share, with adjusted net income of $38.5 million or $0.32 per diluted share. The company increased average daily production to 44,500-45,500 Boe/d, reduced lease operating expenses to $8.00-$8.25 per Boe, and raised capital expenditures to $310-$320 million. HighPeak completed a comprehensive refinancing with a $450 million preferred equity investment and an $800 million credit facility, paying off its $1.2 billion term loan.
ALDX
Aldeyra Therapeutics, Inc. requested the U.S. Food and Drug Administration's Division of Hematologic Malignancies 2 to review its Investigational New Drug application (ADX-2191) for primary vitreoretinal lymphoma, withdrawing its Special Protocol Assessment protocol. This action could adversely affect the company's interactions with the FDA on other programs, including reproxalap, potentially delaying or preventing ADX-2191 approval, increasing costs, and shortening the projected cash runway. The decision on the jurisdictional request is at the FDA's discretion, with no predictable timeline or recommendations.
FWRD
Forward Air Corporation reported strong financial results for the third quarter of 2026, with consolidated operating revenue increasing to $674 million, up from $632 million the previous year. Operating income nearly tripled to $44 million, and consolidated EBITDA reached $101 million, reflecting operational improvements across its segments. Liquidity improved to $446 million, with the lowest net leverage ratio since early 2024, and the company achieved its lowest net loss attributable to noncontrolling interest in the period.
RPM
RPM International Inc. unveiled its MAP 2030 initiative at an Investor Day event in Cherry Hill, New Jersey, targeting a 20% revenue growth and 30% margin improvement by 2030. The program focuses on driving growth and margins while simplifying operational product lines. RPM, a leader in specialty coatings, sealants, and building materials, operates in 167 countries and has increased dividends for 53 consecutive years.
ONCY
Oncolytics Biotech Inc. unveiled translational data from patients with relapsed/refractory multiple myeloma, demonstrating pelareorep's immune system engagement and synergy with standard therapies. The findings, to be presented at the 68th American Society of Hematology Annual Meeting, showed enhanced antigen-presenting activity, increased apoptotic and p53 signaling, and upregulated genes linked to T cell activation. These results support pelareorep's potential as an immunotherapeutic agent, particularly in activating TLR3-mediated antiviral signaling.
HOWL
Werewolf Therapeutics, Inc. announced new clinical data from its Phase 1/1b trial of WTX-124 and Phase 1b/2 trial of WTX-330 at the Society for Immunotherapy of Cancer's 2026 Annual Meeting. WTX-124, a conditionally activated Interleukin-2 molecule, showed durable antitumor activity as monotherapy and in combination with pembrolizumab in patients with relapsed/refractory solid tumors. WTX-330, a conditionally activated Interleukin-12 molecule, demonstrated antitumor activity with reduced treatment-related adverse events in patients with advanced, treatment-refractory solid tumors.
TMCWW
TMC The Metals Company Inc. received a notification from the National Oceanic and Atmospheric Administration (NOAA) regarding its exploration license and commercial recovery permit application under the Deep Seabed Hard Mineral Resources Act. NOAA expects to inform TMC USA by mid-December 2026 of its final determination on the certification of the consolidated application. The company cautions that the timing is an estimate and certification is an intermediate step, not a guarantee of approval or issuance of any license or permit.
FOX
Fox Corporation completed the acquisition of Roku, Inc. in a transaction involving cash and FOX Class A Common Stock, as disclosed in the amended Form 8-K/A filed on November 6, 2026. The filing includes historical financial statements of Roku and pro forma financial information, alongside risk factors related to the integration of Roku's business. While Fox anticipates synergies and operational efficiencies, it acknowledges potential challenges and delays in realizing these benefits, which may impact future results.
MGLD
The Marygold Companies, Inc. announced a definitive merger agreement under which Madison Dearborn Partners will acquire all outstanding shares for $2.00 each, a 100% premium over the closing share price, with the transaction expected to close in the first half of 2027. For the first fiscal quarter ended September 30, 2026, the company reported revenue of $9.4 million, up from $5.2 million a year earlier, with net income from continuing operations rising to $1.7 million, or $0.04 per share, from a net loss of $0.5 million, or $0.01 per share, in the prior year's first quarter. USCF Investments, the largest operating unit, saw revenue nearly double to $8.4 million, driven by increased activity in energy-related ETFs and geopolitical events.
MANE
Veradermics announced positive topline results from its Phase 2/3 clinical trial evaluating VDPHL01, an investigational oral minoxidil formulation, in over 500 males with mild-to-moderate pattern hair loss. The 12-month data showed maintenance of improvement across key efficacy endpoints, with significant increases in non-vellus hair counts in the twice-daily VDPHL01 group. These results, combined with prior positive findings, position VDPHL01 as a potential first FDA-approved oral pill for pattern hair loss in nearly 30 years.
TLS
Telos Corporation reported its third quarter 2026 financial results, achieving $55.2 million in revenue, marking the highest quarterly profit since its IPO, with $9.4 million in cash flow from operations. Revenue grew 7.3% year-over-year, driven by a 16.6% increase in the Security Solutions segment, primarily due to the expansion of large programs in Telos ID. The company raised its full-year guidance, reflecting new awards in Information Assurance and strength in TSA PreCheck volumes, and deployed $5.7 million to repurchase over 1.2 million shares.
AXGN
Axogen, Inc. announced a strategic move to launch in the prostate market, highlighting a significant opportunity and positive clinical outcomes from its nerve reconstruction techniques. The company's forward-looking statements cover clinical development, market expansion, and strategic investments, including the COAPT technique, which shows promising results in erectile function recovery. Axogen's growth drivers include rising prostate cancer diagnoses and advancements in nerve-sparing surgical procedures.
BMNP
Bitmine Immersion Technologies, Inc. has amassed 6.07 million ETH tokens, representing 4.97% of the total ETH supply, valued at $14.3 billion, including $475 million in cash and marketable securities. The company's Chairman, Thomas "Tom" Lee, underscored Ethereum's role as a store of value, aligning with Vitalik Buterin's views on Ethereum's significance in the upcoming tokenization and AI supercycle. Bitmine, the largest ETH treasury globally, continues to expand its holdings through its ETH Treasury Strategy and operates MAVAN, an institutional-grade staking platform, while maintaining strong institutional investor support.
IIPR-PA
Innovative Industrial Properties, Inc. (IIPR) expanded its at-the-market offering program by amending equity distribution agreements to include its 9.25% Series B Cumulative Redeemable Preferred Stock. The program allows for the sale of up to $500 million in common stock and 9.00% Series A Preferred Stock, with approximately $336.9 million still available for sale as of the latest report. These amendments aim to enhance IIPR's capital-raising capabilities through its registration statement on Form S-3.
APVO
Aptevo Therapeutics Inc. presented new preclinical data at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, showcasing its next-generation multispecific platform. The data highlighted the ability of Aptevo's novel antibody-like molecules, APVO451 and APVO452, to activate immune mechanisms and promote tumor-cell killing under immune-suppressive conditions, offering potential for treating difficult-to-treat solid tumors. Additionally, APVO711 demonstrated dual-action potential by activating immune cells and blocking signals that weaken their response, supporting the development of treatments to overcome solid tumor defenses.
VIR
Vir Biotechnology, Inc. announced pivotal Phase 3 ECLIPSE 1 clinical trial results for its investigational combination regimen of elebsiran and tobevibart in chronic hepatitis delta patients, showing a 44% response rate with undetectable virus at Week 48, compared to 0% in the delayed treatment group (p<0.0001). The Phase 2 SOLSTICE study revealed 100% of patients achieving undetectable viremia with HDV RNA at Week 96, alongside significant liver health improvements. The company will discuss these findings in a virtual investor conference call on November 9, 2026.
ONMDW
OneMedNet Corporation announced year-to-date bookings of approximately $18.76 million as of November 6, 2026, with $1.388 million converted to revenue through September 30, 2026. The company reported contracted demand nearly 14 times full-year 2025 bookings, with about half of 2026 contracts from new customers. OneMedNet highlighted its strategy of building strong industry relationships and streamlining contracting processes to deliver scalable, high-quality healthcare data.
NGNE
Neurogene has achieved a significant milestone in its clinical development of NGN-401, a gene therapy for Rett syndrome, by completing dosing in the Embolden registrational trial and initiating a Phase 1/2 trial. The company has received Breakthrough Therapy designation from the FDA and is utilizing its EXACT transgene regulation technology for ICV delivery of a full-length MECP2 gene. Positioned for value inflection, Neurogene anticipates topline data from Embolden in 2H 2027 and aims to complete BLA-enabling Process Performance Qualification runs by year-end 2026.
DFUKF
DeFi Development Corp. (DFDV) increased its SOL holdings by 8,881 SOL as of November 9, 2026, boosting its treasury to approximately 2,609,829 SOL. The company plans to deploy these assets through staking, validator, and onchain treasury infrastructure, contingent on market conditions and risk management. Additionally, DFDV highlighted CHAD's 14.00% annualized dividend rate, emphasizing its role in the company's long-term capital strategy to attract income-focused investors and support SOL accumulation.
KRFG
Heavenly Grace Limited, a subsidiary of King Resources Global, Inc., agreed to acquire collectible items from Grand View Assets Limited for a total of US$12,336,738. The consideration for these acquisitions, comprising 19 pieces of collectibles, will be settled in common stock of KRFG at $0.235 per share. The transactions are detailed in the respective purchase agreements filed as Exhibits 10.1, 10.2, and 10.3 to the current report.
ADCT
ADC Therapeutics SA announced a strategic financial restructuring, including a $86.6 million private investment in public equity (PIPE) financing with Bain Capital Life Sciences and existing investors. The company reported third-quarter 2026 net product revenue of $21 million, up from $15.8 million in the same period in 2025, with cash and cash equivalents of $189.2 million as of September 30, 2026. The restructuring extends the expected cash runway into 2029, with the issuance of approximately 12.9 million common shares and 48 million warrants.
JSPRW
Jasper Therapeutics, Inc. has completed the purchase of its outstanding warrants, acquiring approximately 68.94% of them at $0.324 per warrant, totaling $2.76 million. The transaction, which involved 8.51 million warrants, was settled promptly following the expiration of the offer on November 7, 2026.
INM
Mentari Therapeutics, Inc. completed a merger with its subsidiary, resulting in the combined entity trading on the Nasdaq Capital Market under the ticker symbol "MTRI." The merger was finalized with approximately $490 million in gross proceeds from two private placement financings, led by Fairmount and including participation from several leading investment firms. Mentari is advancing a robust pipeline of biologics for migraine prevention, with Phase 1 clinical trials for MT-001 and MT-002 expected to yield initial data by mid-2027 and year-end 2027, respectively, and has runway into 2029 to develop potentially best-in-class therapies.
RBA
RB Global, Inc. reported a 20% year-over-year increase in gross transaction value (GTV) to $4.7 billion for the third quarter of 2026, driven by broad-based strength across sectors. Revenue grew 17% to $1.3 billion, with net income rising 47% to $140.2 million and diluted earnings per share increasing 63% to $0.70. The company repurchased and retired approximately 3.9 million shares, with $500 million remaining under its Normal Course Issuer Bid.
OFIX
Orthofix Medical Inc. reported third-quarter financial results for the period ending September 30, 2026, with a net loss of $5.2 million, or $0.03 per share, compared to $3.8 million, or $0.02 per share, in the prior year. Revenue increased by 5.1% to $132.4 million, driven by growth in its core orthopedic business. The company's adjusted net income was $2.1 million, or $0.12 per share, with free cash flow rising 15% to $12.3 million.
ONCO
Onconetix, Inc. executed a one-for-ten reverse stock split, effective November 6, 2026, reducing its outstanding shares from approximately 6.7 million to 670,000. The move, approved by the Board on October 22, 2026, adjusted equity awards, convertible securities, and warrants proportionally. The Common Stock began trading on a split-adjusted basis on The Nasdaq Capital Market under the ticker symbol "ONCO" and a new CUSIP number.
PROF
Profound Medical Corp. will showcase its interventional MRI technologies at the Stifel 2026 Healthcare Conference in New York City on November 12, 2026. President Richard Fabian will present, while CEO Arun Menawat and CFO Matthew Sobczyk engage in investor meetings. The company's flagship TULSA-PRO® and Sonalleve® platforms are approved in major markets, with ongoing exploration of new clinical applications.
PLCE
The Children's Place, Inc. has entered into a consulting agreement with Tiger Capital Group, SB360 Capital Partners, and GA Retail Solutions to support inventory sales, with a base fee of 2.5% and a 15% commission on certain sales. On November 8, 2026, the company and its subsidiaries filed for Chapter 11 bankruptcy in New Jersey, accelerating payment obligations under existing credit agreements, subject to the automatic stay provisions of the Bankruptcy Code.
CVI
CVR Energy, Inc. is engaging with potential lenders for a proposed Term Loan B secured credit facility, as detailed in Exhibit 99.1, which is being furnished to the SEC. The company, not classified as an emerging growth company, faces risks and uncertainties, including those related to a potential transaction with Marathon Petroleum Corporation and its affiliates, which could materially affect actual results compared to forward-looking statements.
STRK
Strategy Inc. announced an update to its at-the-market offering program, selling 2,051,348 shares of Variable Rate Series A Perpetual Stretch Preferred Stock and Class A Common Stock, raising $283.8 million in net proceeds. The company allocated $81.9 million for bitcoin purchases, $188.3 million for repurchasing STRC Stock, and $13.6 million to USD Cash. Strategy also reported an increase in bitcoin holdings to 850,364 BTC, with $79.012 million spent on purchases, and maintained $560.3 million for preferred stock repurchases and $1 billion for MSTR Stock repurchases.
CRMD
CorMedix Inc. agreed to acquire substantially all assets of Heron Therapeutics, Inc. for $145.0 million in cash, 14,583,333 shares of common stock, royalties on future sales, and earn-out payments contingent on ZYNRELEF® sales. The transaction, subject to customary closing conditions and stockholder approvals, includes restrictive covenants for Heron post-closing and a $4.0 million termination fee.
IBRX
ImmunityBio, Inc. secured FDA expanded approval for ANKTIVA in combination with BCG for adult patients with BCG-unresponsive non-muscle invasive bladder cancer, including high-grade papillary-only tumors. The company reported a 92% year-over-year growth in nine-month net product revenue, totaling $143.6 million, with Q3 2026 net product revenue reaching $48.7 million, up 53% year-over-year. As of September 30, 2026, ImmunityBio held $334.3 million in cash and cash equivalents, while R&D and SG&A expenses increased by $20.3 million and $17.7 million, respectively, during the quarter.
GT
Goodyear Tire & Rubber Company appointed Roger Wood as interim chief executive officer, replacing Mark W. Stewart, who will step down as CEO and president immediately. The board has initiated a CEO search process with a leading executive search firm. Jerome Rouquet will join as executive vice president and chief financial officer, effective December 1, 2026, succeeding interim CFO Scott Deakin. The board's special committee is conducting a strategic review to optimize business mix, improve efficiency, and invest in new products to drive long-term growth.
NCPLW
Netcapital Inc. secured compliance with Nasdaq's listing requirements after receiving an extension to file its delinquent reports. The fintech company must submit its Annual Report on Form 10-K for the fiscal year ended April 30, 2026, and its Quarterly Report on Form 10-Q for the quarter ended July 31, 2026, by February 9, 2027, to avoid potential delisting. Netcapital is actively working to complete and file these reports promptly.
INO
Inovio Pharmaceuticals, Inc. issued $80.5 million in notes through an underwriting agreement with Jefferies LLC and Piper Sandler & Co., selling 58.7 million shares of common stock and pre-funded warrants for up to 12.7 million shares at $1.05 per share and $1.049 per warrant, respectively. The underwriters have a 30-day option to purchase an additional 10.7 million shares at the public offering price, less discounts and commissions. The offering, expected to close on November 9, 2026, follows the SEC's effective registration statement on Form S-3 from July 10, 2026.
CLLS
Cellectis will report its third quarter 2026 financial results on November 12, 2026, following the close of the U.S. market, with an investor conference call and webcast on November 13, 2026, at 8:00 a.m. ET / 2:00 p.m. CET. The genome engineering company, listed on Nasdaq (CLLS) and Euronext Growth (ALCLS), is headquartered in Paris, France, with locations in New York and Raleigh, NC. Specializing in programmable DNA-binding proteins, Cellectis offers a differentiated platform for gene editing, base editing, epigenetic editing, and transcriptional regulation to address various diseases.
JXG
JX Luxventure Group Inc. agreed to acquire an additional 6,650 shares of Dazzly Investment, Inc.'s common stock, representing 19% of the total outstanding capital stock, under a new share exchange agreement. In exchange, JX Luxventure will issue 4,970,000 shares of its own common stock, valued at $7.52 per share, which constitutes approximately 29% of its outstanding stock, at a 20% discount from its November 6, 2026, closing price. The transaction is contingent upon the fulfillment of certain conditions, including the accuracy of representations and Nasdaq compliance.
TGE-WT
The Generation Essentials Group announced plans to consolidate its shares, reducing authorized share capital from 1.89 trillion to approximately 126 billion shares. The extraordinary general meeting on December 7, 2026, will decide on this consolidation, requiring a quorum of one-third of all votes and a majority of Class B shares for approval. Shareholders will vote via proxy on the proposed resolution.
TMCR
The Metals Royalty Company Inc. reported a net loss of $12.35 billion for the nine months ended September 30, 2026, up from $1.93 billion in the same period in 2025, driven by $77.09 million in finance costs and $21.80 billion in fair value losses on derivatives. Total assets surged to $297.35 billion, primarily due to a $245.49 billion increase in royalty and streaming interests, while liabilities rose to $138.31 billion, largely from contingent consideration and derivative liabilities. The company announced a leadership change, appointing Donald Sewell as President and CFO effective November 9, 2026, and recorded a $318.25 million gain from discontinued operations.
CCGWW
Cheche Group Inc. has agreed to a strategic partnership with CAR Inc., aiming to integrate mobility, insurance, and automotive aftermarket services. The collaboration focuses on mobility services, product innovation, and network collaboration, targeting integrated offerings across the vehicle usage lifecycle. Cheche Group, with a nationwide network in China, and CAR Inc., operating in over 360 cities with a fleet of 220,000 vehicles, will leverage their combined resources to explore new delivery models in the automotive ecosystem.
RVSNW
Rail Vision Ltd. launched an end-to-end Quantum Error Correction (QEC) program on the Arbel superconducting quantum processor at the Israeli Quantum Computing Center (IQCC) through its subsidiary Quantum Transportation Ltd. This initiative marks a significant technological milestone aimed at enhancing the reliability and scalability of quantum computing systems. The program establishes a unified workflow for quantum device characterization, circuit execution, and error decoding, addressing critical challenges in fault-tolerant quantum computing.
GIXI
Gix Internet Ltd. has secured a follow-on order from Sheba Medical Center for three additional autonomous robots, increasing the hospital's fleet from three to six. This expansion supports deliverz.ai's intelligent logistics platform, enhancing operating-room logistics and specimen collection. The existing deployment at Sheba has successfully completed thousands of autonomous missions, including critical medication deliveries, laying the groundwork for further automation across hospital workflows.
B
Barrick Mining Corporation reported strong operational delivery in Q3 2026, with gold production reaching 816 thousand ounces, a 6% increase year-over-year. The company generated $5.07 billion in revenue, $2.49 billion in operating cash flow, and $1.32 billion in net earnings, with adjusted net earnings per share rising 41% year-over-year to $0.82. Barrick reiterated its full-year production guidance and returned $1.04 billion to shareholders, ending the quarter with net cash of $0.9 billion, up from $0.3 billion in Q3 2025.
TLSA
Tiziana Life Sciences LTD announced positive topline results from its Phase 2a INFORM-MS trial, confirming longer-term data trends in patients with treatment-refractory non-active secondary progressive multiple sclerosis (na-SPMS). The trial showed EDSS stabilization, improved Modified Fatigue Impact Scale (MFIS) scores, reduced microglial activation, and a favorable safety profile with intranasal foralumab. Tiziana plans to present detailed findings at an upcoming scientific meeting and evaluate further development for progressive MS and other neurodegenerative conditions.
HNDAF
Honda Motor Co., Ltd. announced plans to build a new $3 billion automobile production plant in Ohio, U.S., and invest in multiple North American facilities to bolster hybrid vehicle production. The Ohio plant, set to begin production in 2029, will create over 2,000 jobs and add capacity for 240,000 vehicles annually. Honda's U.S. production capacity will expand to approximately 1.3 million vehicles a year, with hybrid powertrain production in Ohio increasing by 250 percent.
GRABW
SoftBank Group Corp., Grab Holdings Limited, and Petroleum Sarawak Berhad (PETROS) have agreed to invest US$1 billion in initial seed capital to develop AI infrastructure in Sarawak, Malaysia. The investment, staged according to project milestones, targets a long-term goal of five gigawatts of AI compute capacity and explores opportunities across the AI value chain. The collaboration seeks additional investors and hyperscaler customers to support the project's development and expansion.
VBNK
VersaBank achieved its target of US$1 billion in additional U.S. Structured Receivable Program (SRP) fundings in fiscal 2026, surpassing expectations significantly ahead of schedule. The strong growth in the U.S. SRP, coupled with accelerated growth in Canada, led to a C$969 million increase in total assets during the fourth quarter of fiscal 2026, more than doubling the previous quarter's record. The Bank plans to report its full fiscal 2026 results on January 7, 2027, and aims to add C$7 billion in SRP fundings across the U.S. and Canada by the end of 2027.
EC
Ecopetrol S.A. revised the release date of its third quarter 2026 financial results to November 12, 2026, after market close, and announced a virtual earnings conference call on November 13, 2026. The Colombian energy company, a leader in petrochemicals and gas distribution, also holds stakes in strategic basing operations in the United States, Brazil, and Mexico. Ecopetrol's diverse portfolio includes energy transmission, real-time systems management, and road concessions across Latin America.
NCEL
NewcelX Ltd. secured $1.55 million in private placement financing at a 20% premium to the market price, selling 471,125 common shares and warrants for an additional 353,344 shares at $3.75 each. The funding, led by international healthcare investors and The Crushing T1 Foundation, aims to advance NCEL-101, NewcelX's lead program for type 1 diabetes, including initiating an FDA-required IND-enabling toxicology study and enhancing cell manufacturing capabilities. Proceeds will also support preparations for a planned Phase 1/2a clinical trial in 2027, alongside working capital and general corporate purposes.
FRGT
Freight Technologies, Inc. faces imminent delisting from Nasdaq due to compliance issues, including failing to maintain the Minimum Bid Price Requirement after a one-for-ten reverse share split on October 19, 2026. The company is holding its 2026 Annual Meeting of Shareholders on December 18, 2026, in Monterrey, Mexico, where it recommends approving proposals to elect five directors, ratify TAAD LLP as the independent accounting firm, and conduct an advisory vote on executive compensation. Shareholders must vote on these proposals by the Record Date of October 30, 2026.
OWLS
OBook Holdings Inc. issued $5.75 million in Senior Secured Convertible Promissory Notes to Lind Global Asset Management XV LLC, with a 15% original issue discount, and granted a Class A Common Share Purchase Warrant for up to 1,084,128 shares, raising $5 million in gross proceeds. This marks the company's second financing with the investor, following a $10 million agreement in April 2026. The notes, maturing in 18 months, are convertible into shares at $3.57 each, with potential monthly conversions starting March 2027.
BDRX
Biodexa Pharmaceuticals PLC announced progress in its lead programs, eRapa for familial adenomatous polyposis and MTX240 for gastrointestinal stromal tumors. The company has enrolled 112 of 168 participants in its Phase 3 trial of eRapa, with recruitment ongoing at 29 clinical sites across the US and Europe, and expects database lock and potential topline data by the end of 2027. For MTX240, Biodexa is preparing a Phase 1a dose escalation study, with recruitment set to begin in South Korea mid-2027, following a pre-IND meeting with the FDA on December 10, 2026.
MTEKW
Maris-Tech Ltd. reported a record order backlog of approximately $11 million as of November 8, 2026, marking a significant milestone as the company secured its first governmental tenders as a leading prime contractor. The backlog, defined as pending orders with future fulfillment dates, is not necessarily indicative of future revenues or earnings. This announcement was included in Maris-Tech's Registration Statements on Form S-8 and Form F-3 filed with the SEC.